Edotreotide (SMT 487)

DOTA - 1,4,7,10-tetraazacyclododecanetetracetic acid; structure given in first source; may be labelled with various radioisotopes

Also Known As:

SMT 487; (DOTA(0)-Phe(1)-Tyr(3))octreotide; DOTATOC; SMT-487

Networked: 229 relevant articles (22 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Octreotide: 5228
      - Edotreotide: 229
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Octreotide: 5228
      - Edotreotide: 229

Experts

1.	Baum, Richard P: 9 articles (05/2020 - 01/2013)
2.	Kulkarni, Harshad R: 9 articles (05/2020 - 01/2013)
3.	Haberkorn, Uwe: 9 articles (11/2017 - 01/2003)
4.	Buck, Andreas K: 7 articles (06/2022 - 01/2011)
5.	Brenner, Winfried: 7 articles (09/2020 - 02/2010)
6.	Zhang, Jingjing: 6 articles (05/2020 - 12/2019)
7.	Giesel, Frederik L: 6 articles (11/2017 - 05/2010)
8.	Kratochwil, Clemens: 6 articles (11/2017 - 05/2010)
9.	Haberkorn, U: 6 articles (06/2015 - 07/2001)
10.	Nakamoto, Yuji: 5 articles (03/2021 - 07/2015)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "In this case, the area of increased uptake in the 68Ga-DOTATOC-PET/CT study extended well beyond the tumor margins identified on MRI. " 02/15/2002 - "These studies showed that untreated animals and animals treated with no virus and 500 microCi [(90)Y]-SMT 487 had median tumor quadrupling times of 16 and 25 days, respectively. " 01/01/2023 - "In addition, tumor uptake was observed on 68Ga-labelled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe1-Tyr3-octreotide positron emission tomography/CT (DOTATOC-PET/CT). " 11/14/2021 - "SPECT/CT experiments were performed in tumor-bearing mice using [155Tb]Tb-DOTATOC. " 07/06/2021 - "In addition to its SSTR-specific binding in tumors and healthy tissues, DOTATOC analogues accumulate in kidney parenchyma. "
2.	Meningioma (Meningiomas) 09/01/2012 - "Ga-DOTATOC PET/CT demonstrated an improved sensitivity in meningioma detection when compared to CE-MRI. " 09/01/2023 - "The study included 51 patients who underwent MRI and [68Ga]Ga-DOTATOC PET before meningioma surgery. " 12/01/2023 - "68 Ga-DOTATOC PET/MR imaging was performed in 60 Patients with suspected or diagnosed meningiomas of the skull base and eye socket. " 12/01/2023 - "Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRI." 07/15/2023 - "Benefits of combined use of 68-Ga Dotatoc and 5-ALA fluorescence for recurrent atypical skull-base meningioma after previous microsurgery and Gamma Knife radiosurgery: a case report."
3.	Neuroendocrine Tumors (Neuroendocrine Tumor) 03/01/2020 - "The therapeutic efficacy of 177Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis." 08/01/2023 - "We present a rare case of a 74-year-old woman who underwent 68 Ga-DOTATOC PET/CT imaging for a suspected neuroendocrine tumor (NET) in the pancreatic head. " 08/01/2022 - "[68Ga-DOTATOC PET/CT for Diagnosing Neuroendocrine Tumors]." 01/01/2022 - "Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases." 01/01/2021 - "To present the feasibility of a dynamic whole-body (DWB) 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors (WD-NETs). "
4.	Paraganglioma (Paragangliomas) 05/01/2019 - "PET/CT showed a high Ga-DOTATOC uptake of the mass that was strongly consistent with paraganglioma diagnosis. " 12/01/2008 - "Nevertheless, DOTATOC appears to be a treatment option for surgically incurable paragangliomas, because toxicity is very low and especially the fact that long lasting remissions could be achieved justifies the treatment. " 10/01/2023 - "Multiple myeloma mimicking metastatic skull base paraganglioma in [68 Ga]Ga-DOTATOC-PET/CT and 2-[18F]FDG-PET/CT imaging." 12/01/2008 - "We evaluated the effectiveness and toxicity of radiolabeled DOTATOC in patients with metastatic paraganglioma and pheochromocytoma. " 12/01/2008 - "Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma."
5.	Neoplasm Metastasis (Metastasis) 05/14/2021 - "For bone metastasis imaging, 68 Ga-DOTATOC-PET performed at PET/MRI and PET/CT and 11 C-5-HTP-PET performed equally well (P = 0.05) and better than MRI. " 05/14/2021 - "For liver metastasis imaging, MRI alone was unsurpassed (P < 0.01) and 68 Ga-DOTATOC-PET/MRI and 11 C-5-HTP-PET/MRI outperformed 68 Ga-DOTATOC-PET/CT (P < 0.001). " 01/01/2021 - "18 F-FDOPA PET/CT detected significantly more metastases than 68 Ga-DOTATOC PET/CT in the liver, peritoneum, abdominal and supra-diaphragmatic lymph nodes. " 04/16/2020 - "Patients with histopathologically confirmed NET, at least one liver metastasis > 1 cm and at least two 68Ga-DOTATOC-PET/MRI including ADC maps were eligible. " 03/01/2016 - "Ga-DOTATOC-PET/CT is superior for the detection of NET-metastases compared to (111)In-pentetreotide SPECT. "

Related Drugs and Biologics

1.	Somatostatin Receptors (Somatostatin Receptor)
2.	Radioisotopes (Radionuclides)
3.	Octreotide (Sandostatin)
4.	Peptide Receptors (Peptide Receptor)
5.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
6.	3-Tyr-octreotide
7.	Somatostatin (Somatotropin Release-Inhibiting Factor)
8.	Radiopharmaceuticals
9.	Pentetic Acid (DTPA)
10.	yttrium(III)- 1,4,7,10- tetraazacyclotetradecane- N,N',N'',N'''- tetraacetic acid

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Precision Medicine
4.	Intravenous Injections
5.	Particle Accelerators